A Phase 4 interventional study of Capmatinib 150 mg and Capmatinib 200 mg in Non-Small Cell Lung Carcinoma, sponsored by Novartis Pharmaceuticals. Completed at 15 sites in India. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-10-26.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies testing capmatinib in Carcinoma, Non-Small-Cell Lung — 1 open to participants now, 3 under way, none of them phase 3. capmatinib · Carcinoma, Non-Small-Cell Lung.
Among the 21 studies testing capmatinib in Carcinoma, Non-Small-Cell Lung, this one is the 9th largest by enrollment, is one of 4 that started in 2022, is the only one in phase 4, and was the 17th registered.
7,639 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →1 of the 21 studies testing capmatinib in Carcinoma, Non-Small-Cell Lung is open now, in 1 country. Recruiting first, the newest first:
SWOG Cancer Research Network · Sites in United States
Ages 18+
By country, each count listing its studies:
capmatinib: first FDA approval 2020 (TABRECTA), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →
Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 987 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years to 99 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 14 · Phase 3 2 · Phase 4 1
First in 2012; this study’s year is marked. 4 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 50 is below the median of 62 across 6,034 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 35 across the 21 interventional studies. Of the 15 that completed or were terminated, 11 (73%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 21 have an industry lead sponsor. The 6 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,723 studies on the registry; 222 are open to participants now.
Of its 587 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
101 studies in Carcinoma, Non-Small-Cell Lung by Novartis: 7 open now, 15 under way, none of them phase 3. Of 77 finished, 39 (51%) have results posted.
Among the 101 studies in Carcinoma, Non-Small-Cell Lung by Novartis, this one is the 63rd largest by enrollment of the 92 interventional ones that give a count, is one of 7 that started in 2022, is one of 3 in phase 4, and was the 84th registered.
Novartis’s Carcinoma, Non-Small-Cell Lung studies by the year they started, since 1998.
3 of the studies testing capmatinib in Carcinoma, Non-Small-Cell Lung that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05488314Janssen Research & Development, LLCA Study of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung Cancer | 2027-04-28 |
| NCT05642572SWOG Cancer Research NetworkComparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial) | 2027-06-30 |
| NCT03040973Novartis PharmaceuticalsStudy to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment Alone | 2027-07-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 21 studies testing capmatinib in Carcinoma, Non-Small-Cell Lung, from their registry updates:
Among Novartis’s 101 in Carcinoma, Non-Small-Cell Lung:
This tab as a report to print or save as PDF → With an account.
The Drugs Controller General of India (DCGI) granted approval for Rahika® (capmatinib) film-coated tablets (150 mg and 200 mg) for the treatment of adult patients with advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors harbored a mutation leading to mesenchymal-epithelial transition (MET) exon 14 skipping. As a condition of approval, the DCGI required the conduct of a Phase IV clinical trial in Indian patients. As recommended by the DCGI, this Phase IV study was planned to evaluate the safety and efficacy of capmatinib in adult Indian patients with advanced or metastatic NSCLC with MET exon 14 skipping mutation-positive disease, in any line of therapy.
This was a Phase IV, prospective, multicenter, open-label, interventional study evaluating the safety and efficacy of capmatinib in Indian patients with metastatic non-small cell lung cancer (NSCLC) harboring a MET exon 14 skipping mutation, in any line of therapy. A total of 50 patients were included, with an overall study duration of approximately 2.5 years.
The study consisted of a molecular pre-screening phase of up to 28 days for patients without documented MET exon 14 skipping mutation-positive status, followed by a screening period of up to 28 days, a treatment period of 24 weeks (6 months), an end-of-treatment (EOT) visit, and a follow-up period of 30 days after the last dose of study treatment. Molecular testing was performed centrally using a next-generation sequencing (NGS)-based platform on formalin-fixed, paraffin-embedded (FFPE) tumor samples. Patients with confirmed MET exon 14 skipping mutation, epidermal growth factor receptor (EGFR) wild-type status, and anaplastic lymphoma kinase (ALK)-negative status were eligible for enrollment. Patients negative for MET exon 14 skipping mutation or positive for other biomarkers were excluded and treated according to standard of care.
All eligible participants received capmatinib as the investigational therapy. Capmatinib film-coated tablets (strengths of 150 mg and 200 mg) were administered orally at a starting dose of 400 mg twice daily (BID) on a continuous dosing schedule. Treatment was initiated only after prior anticancer therapy, if applicable, had been discontinued for at least 4 weeks or for a minimum of five times the drug half-life, whichever was longer. The treatment period began on Day 1 of Cycle 1, with each treatment cycle defined as 21 days. Cycle 2 began on Day 22 (Cycle 2 Day 22 [C2D22]), and subsequent cycles followed accordingly in the absence of temporary treatment discontinuation. Dose interruptions and dose reductions to 300 mg BID and subsequently 200 mg BID were permitted per protocol-defined criteria based on patient tolerability. Tablets were administered with or without food and were swallowed whole without chewing, crushing, or breaking.
Treatment was planned for a duration of 24 weeks and continued until disease progression, unacceptable toxicity, withdrawal of consent, or death, or at the discretion of the investigator or the patient. Efficacy assessments were performed every 6 weeks (±7 days) from Cycle 1 Day 1 until disease progression, with radiological assessments conducted using consistent imaging modalities throughout the study. Safety assessments included monitoring of adverse events, laboratory parameters, electrocardiograms (ECGs), and concomitant medications, and patients maintained subject diaries to assess treatment compliance.
Patients who discontinued treatment prematurely underwent end-of-study (EOS) assessments 30 days after administration of the last dose of study treatment. Patients who discontinued treatment without documented disease progression were followed for disease progression until EOS. Completion of the 30-day follow-up period marked EOS.
Post-trial access (PTA) to capmatinib was provided by Novartis to patients who were ongoing on treatment at the end of the planned study duration and were deriving clinical benefit, to ensure uninterrupted therapy beyond the study period. Patients transitioning to PTA were also required to complete the EOS visit assessments after the last dose of capmatinib administered within the study.
The criteria were revised on the registry on Oct 2, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients must have adequate organ function, including the following laboratory values at the screening visit:
Exclusion criteria
Women of , defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of while taking study treatment and for 7 days after stopping study treatment. Highly effective contraception methods include:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Capmatinib (Rahika®) film-coated tablet administered as 400 mg orally twice daily on a continuous dosing schedule for 24 weeks.
Drug: Capmatinib 150 mg · Drug: Capmatinib 200 mg
Capmatinib film-coated tablet 150 mg administered BID with or without food for 24 weeks. It should be swallowed whole and should not be broken, chewed, or crushed.
Also known as: Rahika® 150mg
Capmatinib film-coated tablet 200 mg administered BID with or without food for 24 weeks. It should be swallowed whole and should not be broken, chewed, or crushed.
Also known as: Rahika® 200 mg
Percentage of Participants With at Least One Treatment-Emergent Adverse Events (TEAEs) and Serious Treatment-Emergent Adverse Events (Serious TEAEs)
Treatment-emergent adverse events (TEAEs) were adverse events that occurred or worsened following initiation of study treatment and up to 30 days after the last dose of the study drug. Serious treatment-emergent adverse events (serious TEAEs) were TEAEs that met the criteria for a serious adverse event, defined as any adverse event that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability or incapacity, was a congenital anomaly or birth defect, or was an abnormal pregnancy outcome.
Time frame: From start of treatment up to 30 days after last dose of study treatment, assessed up to approximately 7 months
Percentage of Participants With Dose Modifications
Percentage of participants experiencing dose modifications, including dose interruptions and dose reductions. Dose modifications were implemented to manage intolerance to the protocol-specified regimen and were based on the worst preceding toxicity graded according to NCI-CTCAE v5.0. Capmatinib dose reductions followed predefined dose levels (400 mg BID → 300 mg BID → 200 mg BID), with a maximum of two consecutive reductions and no reductions below 200 mg BID. Treatment was discontinued if clinically significant toxicity recurred at the lowest dose despite maximal supportive measures, or if treatment interruption exceeded 21 consecutive days, unless continuation was approved by the Novartis Medical Lead or designee. Dose re-escalation was permitted once after at least one treatment cycle (3 weeks) at the reduced dose, provided no dose-modifying adverse event occurred.
Time frame: From first dose of study treatment administration until end of treatment, assessed up to approximately 6 months
Dose Intensity
Dose intensity was defined as the ratio of actual cumulative dose received to the actual duration of exposure.
Time frame: From first dose of study treatment administration until end of treatment, assessed up to approximately 6 months
Overall Response Rate (ORR)
Overall Response Rate (ORR) was defined as the proportion of subjects with a confirmed best overall response of complete response (CR) or partial response (PR), per RECIST v1.1 by investigator assessment. * Complete Response (CR) - Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) were required to have a reduction in short axis to \< 10 mm (the sum could not be "0" if target nodes were present). * Partial Response (PR) - At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters.
Time frame: From first dose of study treatment through study completion (up to approximately 34 months)
Overall Intracranial Response Rate (OIRR)
Overall Intracranial Response Rate (OIRR) was calculated as the overall response rate (ORR; complete response \[CR\] plus partial response \[PR\]) of lesions in the brain among patients with measurable intracranial disease at baseline, per RECIST v1.1 by investigator assessment. * Complete Response (CR) - Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) were required to have a reduction in short axis to \< 10 mm (the sum could not be "0" if target nodes were present). * Partial Response (PR) - At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters.
Time frame: From first dose of study treatment through study completion (up to approximately 34 months)
Duration of Response (DOR)
Duration of Response (DOR) was defined as the time from the first documented response (complete response \[CR\] or partial response \[PR\]) to the first documented disease progression or death, as assessed by the investigator per RECIST version 1.1. Patients who did not experience disease progression or death from any cause were censored at the date of the last adequate tumor assessment prior to the start of any new antineoplastic therapy. It should be noted that the response counts presented in this section are based on confirmed best overall response (BOR) per RECIST v1.1 criteria. In contrast, response counts used in time-to-event analyses (e.g., DOR and time to response \[TTR\]) may differ, as these analyses are based on observed CR or PR at any assessment timepoint derived from raw data.
Time frame: From first documented response to disease progression or death, assessed through study completion (up to approximately 34 months)
Time To Response (TTR)
Time to Response (TTR) was defined as the time from the first dose of capmatinib to the first documented response of CR or PR, per RECIST v1.1 by investigator assessment.
Time frame: From first dose of study treatment through first documented response, assessed through study completion (up to approximately 34 months)
Disease Control Rate (DCR)
Disease Control Rate (DCR) was defined as the proportion of patients with CR or PR or stable disease (SD), per RECIST v1.1 by investigator assessment. * Complete Response (CR) - Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) were required to have a reduction in short axis to \< 10 mm (the sum could not be "0" if target nodes were present). * Partial Response (PR) - At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. * Stable Disease (SD) - Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD), taking as reference the smallest sum of diameters recorded while on study.
Time frame: From first dose of study treatment through study completion (up to approximately 34 months)
Progression Free Survival (PFS)
Progression-Free Survival (PFS) was defined as the time from the first dose of capmatinib to the first documented disease progression per RECIST v1.1 by investigator assessment or death from any cause. If a patient had not progressed or was not known to have died at the date of the analysis cut-off or had received any further anticancer therapy, PFS was censored at the date of the last adequate tumor evaluation before the cut-off date or before the start of the new anticancer therapy, whichever occurred earlier. PFS was censored at the last adequate tumor assessment if one of the following occurred: (1) absence of an event, (2) the event occurred after initiation of a new anticancer therapy, or (3) the event occurred after two or more missing tumor assessments.
Time frame: From first dose of study treatment to first documented progression or death, assessed through study completion (up to approximately 34 months)
This study was conducted at 26 centers in India.
| Milestone | Capmatinib |
|---|---|
| Started | 50 |
| Full analysis set (fas) | 44 |
| Completed | 27 |
| Not completed | 23 |
| Withdrew: Withdrawal by subject | 4 |
| Withdrew: Adverse event | 1 |
| Withdrew: Progressive disease | 13 |
| Withdrew: Death | 5 |
Treatment-emergent adverse events (TEAEs) were adverse events that occurred or worsened following initiation of study treatment and up to 30 days after the last dose of the study drug. Serious treatment-emergent adverse events (serious TEAEs) were TEAEs that met the criteria for a serious adverse event, defined as any adverse event that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability or incapacity, was a congenital anomaly or birth defect, or was an abnormal pregnancy outcome.
| Percentage of participants | Capmatinib |
|---|---|
| At least one Treatment-emergent adverse events (TEAEs) | 88 (75.7 to 95.5) |
| At least one Serious treatment-emergent adverse events (serious TEAEs) | 28 (16.2 to 42.5) |
Percentage of participants experiencing dose modifications, including dose interruptions and dose reductions. Dose modifications were implemented to manage intolerance to the protocol-specified regimen and were based on the worst preceding toxicity graded according to NCI-CTCAE v5.0. Capmatinib dose reductions followed predefined dose levels (400 mg BID → 300 mg BID → 200 mg BID), with a maximum of two consecutive reductions and no reductions below 200 mg BID. Treatment was discontinued if clinically significant toxicity recurred at the lowest dose despite maximal supportive measures, or if treatment interruption exceeded 21 consecutive days, unless continuation was approved by the Novartis Medical Lead or designee. Dose re-escalation was permitted once after at least one treatment cycle (3 weeks) at the reduced dose, provided no dose-modifying adverse event occurred.
| Participants | Capmatinib |
|---|---|
| Percentage of Participants With Dose Modifications | 14 |
Dose intensity was defined as the ratio of actual cumulative dose received to the actual duration of exposure.
| mg/Day | Capmatinib |
|---|---|
| Dose Intensity | 762.4481 ± 66.48123 |
Overall Response Rate (ORR) was defined as the proportion of subjects with a confirmed best overall response of complete response (CR) or partial response (PR), per RECIST v1.1 by investigator assessment. * Complete Response (CR) - Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) were required to have a reduction in short axis to \< 10 mm (the sum could not be "0" if target nodes were present). * Partial Response (PR) - At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters.
| Percentage of participants | Capmatinib |
|---|---|
| Overall Response Rate (ORR) | 40.9 (26.3 to 56.8) |
Overall Intracranial Response Rate (OIRR) was calculated as the overall response rate (ORR; complete response \[CR\] plus partial response \[PR\]) of lesions in the brain among patients with measurable intracranial disease at baseline, per RECIST v1.1 by investigator assessment. * Complete Response (CR) - Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) were required to have a reduction in short axis to \< 10 mm (the sum could not be "0" if target nodes were present). * Partial Response (PR) - At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters.
| Participants | Capmatinib |
|---|---|
| Overall Intracranial Response Rate (OIRR) by RECIST 1.1 | 1 |
| Overall Intracranial Response Rate (OIRR) by RECIST 1.1 for Treatment Naive Subjects | 1 |
| Overall Intracranial Response Rate (OIRR) by RECIST 1.1 for Prior Treated Subjects | 0 |
Duration of Response (DOR) was defined as the time from the first documented response (complete response \[CR\] or partial response \[PR\]) to the first documented disease progression or death, as assessed by the investigator per RECIST version 1.1. Patients who did not experience disease progression or death from any cause were censored at the date of the last adequate tumor assessment prior to the start of any new antineoplastic therapy. It should be noted that the response counts presented in this section are based on confirmed best overall response (BOR) per RECIST v1.1 criteria. In contrast, response counts used in time-to-event analyses (e.g., DOR and time to response \[TTR\]) may differ, as these analyses are based on observed CR or PR at any assessment timepoint derived from raw data.
| Months | Capmatinib |
|---|---|
| Duration of Response (DOR) | 5.35 (3.12 to NA) |
Time to Response (TTR) was defined as the time from the first dose of capmatinib to the first documented response of CR or PR, per RECIST v1.1 by investigator assessment.
| Months | Capmatinib |
|---|---|
| Time To Response (TTR) | 3.45 (1.51 to 8.38) |
Disease Control Rate (DCR) was defined as the proportion of patients with CR or PR or stable disease (SD), per RECIST v1.1 by investigator assessment. * Complete Response (CR) - Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) were required to have a reduction in short axis to \< 10 mm (the sum could not be "0" if target nodes were present). * Partial Response (PR) - At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. * Stable Disease (SD) - Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD), taking as reference the smallest sum of diameters recorded while on study.
| Percentage of participants | Capmatinib |
|---|---|
| Disease Control Rate (DCR) | 90.9 (78.3 to 97.5) |
Progression-Free Survival (PFS) was defined as the time from the first dose of capmatinib to the first documented disease progression per RECIST v1.1 by investigator assessment or death from any cause. If a patient had not progressed or was not known to have died at the date of the analysis cut-off or had received any further anticancer therapy, PFS was censored at the date of the last adequate tumor evaluation before the cut-off date or before the start of the new anticancer therapy, whichever occurred earlier. PFS was censored at the last adequate tumor assessment if one of the following occurred: (1) absence of an event, (2) the event occurred after initiation of a new anticancer therapy, or (3) the event occurred after two or more missing tumor assessments.
| Months | Capmatinib |
|---|---|
| Progression Free Survival (PFS) | 6.31 (4.60 to NA) |
Collected over On-treatment Adverse Events (AEs) and deaths were collected from first dose of study medication until the last dose plus 30 days safety follow-up, assessed up to approximately 7 months.. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Capmatinib | 7/50 (14%) | 14/50 (28%) | 42/50 (84%) |
| Event | Capmatinib |
|---|---|
| Cardiac arrestCardiac disorders | 2/50 |
| Sudden deathGeneral disorders and administration site conditions | 2/50 |
| AnaemiaBlood and lymphatic system disorders | 1/50 |
| Pericardial effusionCardiac disorders | 1/50 |
| Small intestinal obstructionGastrointestinal disorders | 1/50 |
| Non-cardiac chest painGeneral disorders and administration site conditions | 1/50 |
| PyrexiaGeneral disorders and administration site conditions | 1/50 |
| BronchitisInfections and infestations | 1/50 |
| Lower respiratory tract infectionInfections and infestations | 1/50 |
| SepsisInfections and infestations | 1/50 |
| Event | Capmatinib |
|---|---|
| Oedema peripheralGeneral disorders and administration site conditions | 22/50 |
| VomitingGastrointestinal disorders | 13/50 |
| FatigueGeneral disorders and administration site conditions | 10/50 |
| HypoalbuminaemiaMetabolism and nutrition disorders | 10/50 |
| HypocalcaemiaMetabolism and nutrition disorders | 10/50 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 9/50 |
| NauseaGastrointestinal disorders | 8/50 |
| DiarrhoeaGastrointestinal disorders | 7/50 |
| PyrexiaGeneral disorders and administration site conditions | 7/50 |
| CoughRespiratory, thoracic and mediastinal disorders | 7/50 |
| Age, Continuous(Years) | Capmatinib |
|---|---|
| Mean | 65.7 ± 8.96 |
| Sex: Female, Male(Participants) | Capmatinib |
|---|---|
| Female | 17 |
| Male | 33 |
| Race (NIH/OMB)(Participants) | Capmatinib |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 50 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 0 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Ran from Sep 2022 to primary completion in Aug 2025, 35 months.
Results were first posted in Oct 2026, 1 year 1 month after primary completion.
Of 43 phase 4 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 48. This study's 35 months is close to that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Capmatinib
Carcinoma, Non-Small-Cell Lung →